Results 71 to 80 of about 4,832 (178)

Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma [PDF]

, 2019
PURPOSE: In the Phase III SIROCCO trial (NCT01928771), benralizumab significantly reduced asthma exacerbations and improved lung function and symptoms for patients with severe, uncontrolled eosinophilic asthma.
Lee, SY, Barker, P, Park, HS, Lee, SH, Werkstrom, V, Kim, MK, Zangrilli, JG, Lee, BJ   +7 more
core   +1 more source

Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine

Respirology, Volume 31, Issue 6, Page 561-577, June 2026.
ABSTRACT Chronic obstructive pulmonary disease (COPD) remains the third leading cause of death worldwide, and conventional bronchodilator‐based therapies have limited efficacy in preventing exacerbations and disease progression. The 2024–2026 period represents a historic inflection point: three mechanistically distinct agents received Food and Drug ...
Naoya Fujino, Hisatoshi Sugiura
wiley   +1 more source

Benralizumab: a unique IL-5 inhibitor for severe asthma

, 2016
Laren D Tan,1 Jennifer M Bratt,2 Dorottya Godor,3 Samuel Louie,2 Nicholas J Kenyon2 1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA, USA; 2Division of Pulmonary,
Kenyon NJ, Bratt JM, Louie S, Tan LD, Godor D   +4 more
core  

A novel JAK1 variant in chronic eosinophilic leukaemia with response to benralizumab

British Journal of Haematology, EarlyView.
Isabel C. Vallecillo‐Viejo, Michael D. Claiborne, Charles F. Anderson, Samantha Shafer, Alan Saven, Bryce A. Seifert, Morgan Similuk, Magdalena Walkiewicz, Irina Maric, Pia R. Crespo, Lori Broderick, Andrew A. White, Amy D. Klion   +12 more
wiley   +1 more source

Geographic and economic influences on benralizumab prescribing for severe asthma in Japan

Scientific Reports
Benralizumab, a monoclonal antibody targeting IL-5 receptors, reduces exacerbations and oral corticosteroid requirements for severe, uncontrolled eosinophilic asthma.
Nobuaki Kobayashi, Hiromi Matsumoto, Kohei Somekawa, Ayami Kaneko, Nobuhiko Fukuda, Suguru Muraoka, Yukiko Ohtsu, Momo Hirata, Ryo Nagasawa, Sousuke Kubo, Kota Murohashi, Hiroaki Fujii, Ayako Aoki, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Takeshi Kaneko   +16 more
doaj   +1 more source

Are Phenotypic Baseline Characteristics Related to Abolition of AHR After Benralizumab and Dupilumab?

Clinical &Experimental Allergy, EarlyView.
Philipp Suter, Robert Greig, Rory Chan, Brian J. Lipworth   +3 more
wiley   +1 more source

PRS50 Benralizumab for treating severe eosinophilic asthma: nice single technology appraisal

, 2019
ObjectivesTo critically review evidence on clinical and cost effectiveness of benralizumab (Fasenra®) in adults with severe eosinophilic asthma, submitted by AstraZeneca to the National Institute for Health and Care Excellence (NICE).MethodsAstraZeneca ...
Long, L., Ocean, N., Hoyle, M., Bello, S., Dodman, S., Barnish, M., Nikram, E., Tikhonova, I., Robinson, S.   +8 more
core   +1 more source

Hur effektiv och säker är benralizumab vid långtidsbehandling av eosinofil astma? : Påverkar behandling med benralizumab behovet av glukokortikoider?

Astma är vanliga sjukdomar som drabbar olika åldrar och sjukdomen är vanlig i hela världen och studier har visat att 50% av patienter med svår astma har högre värden på T-hjälpar cellen Th2 och högre nivå av IgE.
Abo Aleneen, Rama
core   +2 more sources

Single-Use Autoinjector Functionality And Reliability For At-Home Administration Of Benralizumab For Patients With Severe Asthma: GRECO Trial Results

Journal of Asthma and Allergy, 2019
Gary T Ferguson,1 Jeremy Cole,2 Magnus Aurivillius,3 Paul Roussel,4 Peter Barker,4 Ubaldo J Martin4 On behalf of the GRECO study investigators1Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA; 2OK Clinical Research, LLC,
Ferguson GT, Cole J, Aurivillius M, Roussel P, Barker P, Martin UJ   +5 more
doaj  

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience

, 2023
Background: Mepolizumab and benralizumab are monoclonal antibodies directed against anti-IL-5 and anti-IL5R, respectively, and their use reduces the exacerbation rate and maintains oral corticosteroid requirements in severe eosinophilic asthma.
Maglio A., Vatrella A., Crimi C., Pelaia G., Foschino Barbaro M. P., Caiaffa M. F., Triggiani M., Scioscia G., Crimi N., Nolasco S., Papia F., Pelaia C., Carpagnano G. E., Valenti G., Tondo P.   +14 more
core   +1 more source